Ruixue Li

Dr. Ruixue Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
MWMin Wu
Min Wu
RLRuixue Li
Ruixue Li
JQJianyan Qin
Jianyan Qin
ZWZiyuan Wang
Ziyuan Wang
JGJiasen Guo
Jiasen Guo
YHYonguang Huang
Yonguang Huang

11 November 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
RLRuixue Li
Ruixue Li
JQJianyan Qin
Jianyan Qin
ZWZiyuan Wang
Ziyuan Wang
FLFenghong Lv
Fenghong Lv
JGJiasen Guo
Jiasen Guo
YHYouguang Huang
Youguang Huang
Chemotherapy resistance is the primary cause of high mortality in patients with advanced colon cancer. The combination of small molecule compound dioscin (DIO) and traditional medicine may have a chemosensitizing effect. In this study, we reported that DIO, in combination with Oxaliplatin (L-OHP) and 5-fluorouracil (5-Fu), can effectively inhibit colon cancer cell proliferation, and co-treatment was positively related to the DIO concentration. HCT116 co-treatment with 6.4 μM L-OHP and 0.8 μM DIO significantly reduced colony formation and migration, increased apoptosis, and cell-cycle arrest in the G0/G1 and G2/M phase. DIO-assisted L-OHP significantly inhibited the xenograft model growth and exhibited low toxicity.The mRNA-sequencing combined with network pharmacological analysis suggested that the DIO sensitivity may be related to the active targets FAS, CDKN1A, ABCA1, and PPARA, which are primarily involved in regulating the cell cycle and apoptosis. Finally, our experiments suggest that DIO may enhance the L-OHP sensitivity by regulating the cell cycle through the Notch pathway.

28 January 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YZYoulong Zhu
Youlong Zhu
ZQZongze Qi
Zongze Qi
SZShaoqi Zu
Shaoqi Zu
FYFangchao Yang
Fangchao Yang
YWYanming Wang
Yanming Wang
HZHong Zhu
Hong Zhu
Pancreatic adenocarcinoma (PAAD) is a highly malignant tumor in the digestive system, with an increasing incidence and mortality rate globally. Recent genetic studies have revealed that the abnormal expression and functional dysregulation of various genes are involved in the occurrence and progression of pancreatic cancer. NIPA-like proteins (NIPAs) are expressed in a variety of cancer types, yet the role of NIPAL1 in cancer remains unclear. Therefore, further research is required to determine its diagnostic significance and understand its biological functions in cancer. Primitive RNA sequencing (RNA-seq) data of PAAD from The Cancer Genome Atlas (TCGA) was utilized for bioinformatics analysis to characterize the expression levels of NIPAL1 in tumor and normal tissues. Differentially expressed genes (DEGs) were identified, and Gene Set Enrichment Analysis (GSEA) was performed to elucidate potential biological mechanisms of NIPAL1 involved in PAAD development. Additionally, we analyzed the correlation between NIPAL1 expression, immune cell infiltration, and PAAD progression. The Genomics of Drug Sensitivity in Cancer (GDSC) database was utilized to investigate the relationship between NIPAL1 expression and the efficacy of common drugs used in chemotherapy and targeted therapy in patients with pancreatic cancer. Subsequently, we predicted five small-molecule drugs targeted at NIPAL1 using molecular docking. Finally, high expression of NIPAL1 in tumor tissues was validated through immunohistochemistry. In pancreatic cancer cell lines, changes in phenotypes such as proliferation, migration, and invasion following the knockdown of NIPAL1 were assessed. Finally, we established a subcutaneous tumor-bearing mouse model to further validate its therapeutic significance in vivo.

4 September 2025 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
SZShijie Zhong
Shijie Zhong
WYWei Yang
Wei Yang
ZLZhangchao Li
Zhangchao Li
RLRuixue Li
Ruixue Li
BFBimang Fu
Bimang Fu
Background: Liposarcoma (LPS) is a rare mesenchymal soft tissue sarcoma, and dedifferentiated liposarcoma (DDLPS) represents a clinically significant and aggressive subtype. Retroperitoneal DDLPS poses significant clinical challenges due to its insidious onset, large tumor size at the time of diagnosis, complex anatomical relationships, and high rates of recurrence and multi-organ involvement.Case presentation: We present the case of a 64-year-old male who presented with a progressively enlarging abdominal mass, fatigue, and reduced appetite persisting for over five years. Imaging studies and interdisciplinary evaluation revealed a massive retroperitoneal tumor with invasion into multiple adjacent organs. The patient underwent comprehensive surgical resection involving the tumor, left kidney, spleen, and distal pancreas, along with diaphragmatic repair. Histopathological analysis confirmed high-grade dedifferentiated liposarcoma. Postoperatively, the patient developed mild complications, including pneumothorax, which were effectively managed. Postoperative imaging and laboratory examinations demonstrated that the tumor was completely resected, with the majority of organ functions effectively preserved.Conclusion: This case highlights the complexity of treating a large and multi-organ-involving retroperitoneal dedifferentiated liposarcoma. Radical surgical resection remains the most effective treatment approach, but while achieving complete resection, it is also necessary to take into account the maximum protection of the patient's vital organ functions.